http://genera.proactiveinvestors.com.au/genera//files/companies/blt_starsin2012_sydney18july.pdfPage 20 (Progress in ddRNAi-based programs) includes "advanced cancer (Gradalis)".
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%